References
- 해리슨내과학편찬위원회. 1997. Harrison's 내과학, 서울. 도서출판 정담 : 1977-1993
- Rosenberg SA, Lotze MT, Mule JJ 1988. New approach to the immunotherapy of cancer using interleukin-2. Ann Int Med 108 : 853-864
- Whittington R, Faulds D. 1993. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46 : 446-514
- Brandau S, Suttmann H, Flad HD, et al. 2000. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2-and BCG-activated effector cells. Cancer Immunol Immunother 49 : 369-376
- Dutcher JP, Logan T, Gordon M, et al. 2000. Phase II trial of interleukin 2, interferon alpha. and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 6 : 3442-3450
- Margolin KA. 2000. Interleukin-2 in the treatment of renal cancer. Semin Oncol 27 : 194-203
- Anderson PM, Sorenson MA. 1994. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 27 : 19-31
- Kripke ML. 1977. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37 : 1395-1400
- Samlowski WE, Yim CY, McGregor JR, et al. 1995. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL- 2 treatment of mice. J Immunother 18: 166- 178
- Papa MZ, Vetto JT, Ettinghausen SE, et al. 1986. Effect of corticosteroid on the antitumor actrvity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res 46: 5618-5623
- Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 : 457
- Kalbfleisch JD, Prentice RL. 1980. The statistical analysis of failure time data. John Wiley & Sons. New York: 143
- Thomson A. 1991. Interleukin-2. In : The cytokine handbook. Academic Press. London : 83-102
- Lotze MT, Grimn EA. Mazumder A, et al. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41 : 4420-4425
- Mertelsmann R, Welte K. 1986. Human interleukin-2 molecular biology. physiology and clinical possibilities. Immunol 172 : 400-419
- Paul WE. 1993. T-cell derived cytokines and their receptors. In: Fundamental immunology, 3rd ed. Raven Press. New York : 763-800
- Blay JY, Favrot MC, Negrier S, et al. 1990. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 50 : 2371-2374
- Cifone MG, D'Alo S, Parroni R, et al. 1999. Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production. Blood 93 : 3876-3884
- Gelmo BT, Palladino MA Jr, Jeffe HS, et al. 1988. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48: 5864-5867
- Hibbs JB Jr, Taintor RR, Vavrin Z, et al. 1988. Nitric oxide. A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157 : 87-94
- Hibbs JB Jr, Westenfelder C, Taintor RR, et al. 1992. Evidence for cytokine inducible nitric oxide synthesis from Larginine in patients receiving interleukin-2 therapy. J Clin Invest 89 : 867-877
- Jansson OT, Morcos E, Brundin L, et al. 1998. Nitric oxide synthase activity in human renal cell carcinoma. J Urol 160 : 556-560
- Jyothi MD, Khar A. 2000. Interleukin-2-induced nitric oxide synthase and nuclear factor-kappa B activity in activated natural killer cells and the production of interferon-gamma. Scand J Immunol 52 : 148-155
- Kasid A, Director EP, Rosenberg SA. 1989. Induction of endogeneous cytokine mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 143: 736-739
- Lee SG, Hea DS, Yoon SJ, et al. 2000. Effect of GM-CSF and IL-2 coexpression on the anti-tumor immune response. Anticancer Res 20 : 2681-2686
-
Mier JW, Vachino G, Van Der Meer JWM, et al. 1988. Induction of circulating tumor necrosis factor(TNF-
$\alpha$ ) as the mechanism for the febrile response to interleukin-2(IL-2) in cancer patients. J Clin Immunol 8 : 426-436 - Robak T. 1995. Biological properties and therapeutic use of interleukin 2(IL-2). Postepy Hig Med Dosw 49: 367-393
- Yim CY, Lee CW, Choi SM, et al. 1996. Effects of nitric oxide(NO) synthesis inhibition on antitumor responses during interleukin-2(IL-2) treatment of mice. Korean J Intern Med 11 : 93-100
- Boccoli G, Masciulli R, Ruggeri EM, et al. 1990. Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment. Cancer Res 50 : 5795-5800
- Yim CY, Bastian NR, Smith JC, et al. 1993. Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers. Cancer Res 55 : 5507-5511
- Kwon OD. 2000. Effect of interleukin-2 on antitumor response against subcutaneous Meth-A tumor in mice. Korean J Vet Clin Med 17: 305-310
- Kwon OD. 2001. Effect of interleukin-2 on antitumor response against ultraviolet radiation-induced fibrosarcoma in mice. J Vet Clin Med 18: 14-17
- Yim CY, McGregor JR, Kwon OD, et al. 1995. Nitric oxide synthesis contributes to IL-2-induced antitumor response against intraperitoneal Meth A tumor. J Immunol 155: 4382-4390